Abbott Seeks Expanded Approval on Humira and Johnson & Johnson to Participate in the Bear Stearns 19th Annual Health Care Conference.

0 Comments | M2 Presswire, September, 2006

M2 PRESSWIRE-8 September 2006-U.S. Equity News: Abbott Seeks Expanded Approval on Humira and Johnson & Johnson to Participate in the Bear Stearns 19th Annual Health Care Conference(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:08092006 City of Industry, CA - Pharmaceuticals Instruments industry alert provided by U.S.

Equity News. Diversified health care products company Abbott Laboratories (NYSE:ABT) said Thursday it asked for expanded in approval in both the United States and Europe for its arthritis drug, Humira. The company is seeking to market the drug as a treatment for Crohn's disease, a chronic inflammatory gastrointestinal tract disease, which affects over a million people in Europe and North America. The disease has no cure. Scientists from GlycoFi, Inc.,...

Read the rest of this article with a Free Trial at HighBeam Research.
Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:
  1. You are currently: a Guest |
  4.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)